Form PTO			OF COMME	RCE	ATTY. DOCKET NO.		T			
(MODIFIED) PATENT AND TO EMARK OFFICE					078883/011					
INI	FORMA	TION DISCLOSUR	RE CITATION	APPLICANO REC'O PCT/PTO 2 4 MAR 2000 Christopher Robert BEBBINGTON et al.						
				FILING DATE	GROUP ART UNIT					
	(Use	several sheets if nec	essary)	March 24, 2000		UNASSIGNED				
			U.S. PA	ATEN	T DOCUMENTS	AH	ach #	15		
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUB- CLASS	ł	FILING DATE IF APPROPRIATE	
	+									
						·	ļ			
							<del> </del>	-		
	<del> </del>	-						<del> </del>		
	<del> </del> -									
	.L		FOREIGN		N=					
	T	DOCUMENT	POREIGN	PAIL	NT DOCUMENTS					
	REF	NUMBER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANS	LATION	
<u> </u>	A1	96/28563	09/1996	WIPO				150	NO	
CMN	A2	98/15636	04/1998	WIPO						
		OTHER DOCUM	MENTS (Including	a Auth	nor, Title, Date, Pertin					
1		MORGENSTERN J	P., et al. "Advance	ed ma	mmalian gene transfer	ent Pages, E	=tc.)			
W	А3	MORGENSTERN J.P., et al, "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line, <i>Nucleic Acids Research</i> .								
		Vol. 18, No. 12, pp. 3587-3596, (May 7, 1990)								
W)	A4	BILBAO, G., et al, "Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable								
		transduction in vivo, The FASEB Journal, Vol. 11, pp. 624-634, (July 11, 1997)								
mu,	A5	Promega Product Catalog, "Mammalian Expression", pp. 254 and 255, (1997)								
un	A6	ZHENG, B, et al., "Increment of hFIX expression with endogenous intron 1 in vitro1", Cell Research, Vol. 7.								
m,	70	No. 1, pp. 21-29, (June 1997)								
	}									
CAMINER		11 1			DATE CONSIDERED					
			<b>-</b>	- 1	4.70.0	17				
EXAMI	NER: I	nitial if citation co	onsidered, whet onformance an	ther o	r not citation is in c considered. Include		e with MPI	EP 609;	Draw	
commi	unicatio	on to applicant.				ae any copy	or this fo	m with	next	

002.319363